Champions Oncology, INC.: insider trades · United States · SEC (Form 4)

About Champions Oncology, INC.

Champions Oncology, Inc. (ticker: CSBR) is a United States-based company listed on the Nasdaq market in the United States, focused on translational oncology and research services for biopharmaceutical clients. Headquartered in Hackensack, New Jersey, the company has built a niche position around helping pharma and biotech partners better understand tumor biology, treatment response, and resistance mechanisms earlier in the drug-development cycle. Its roots date back to the late 1990s, and over time the business has evolved from a tumor-model platform into a broader oncology solutions provider combining preclinical research, clinical support, and data monetization. The company’s core franchise is centered on patient-derived xenograft (PDX) models, in which human tumors are implanted into immunodeficient mice to better replicate how cancers behave in patients. Champions Oncology operates one of the industry’s largest and most highly annotated PDX model banks and offers integrated in vivo and ex vivo workflows. Its main business lines include drug discovery and optimization support, translational pharmacology studies, clinical bioanalytical services, and an emerging data licensing business built on multiomic and functionally annotated tumor datasets. From a competitive standpoint, Champions occupies a specialized but relevant position among oncology research providers. It is differentiated less by scale than by scientific depth, clinical relevance, and the ability to generate actionable data earlier in development. That makes it attractive to biopharma customers seeking to reduce translational risk and make better pipeline decisions. The company also maintains research operations in the United States and a bioinformatics/computational biology presence in Israel, strengthening its data-oriented capabilities. Recent milestones have been important. In 2025, Champions Oncology reported record revenue, improved profitability, and a clear push toward growth in higher-margin data and platform services. The company also launched a radiopharmaceutical services platform, expanded its isotope-related capabilities, and continued to present new scientific data at major industry meetings such as AACR 2026. For investors, CSBR is a small-cap Nasdaq-listed healthcare name with exposure to biotech spending cycles, but also with a differentiated platform in precision oncology and translational research.